Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

Cancer Chemother Pharmacol. 2020 May;85(5):1009-1010. doi: 10.1007/s00280-020-04056-6.

¹ University of Arizona Comprehensive Cancer Center, Tucson, AZ, USA. hanibabiker@email.arizona.edu.
² University of Iowa Hospital, Iowa City, IA, USA.
³ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
⁴ Greenville Health System, Greenville, SC, USA.
⁵ Cleveland Clinic, Cleveland, OH, USA.
⁶ Vanderbilt University Medical Center, Nashville, TN, USA.
⁷ MD Anderson Cancer Center, Houston, TX, USA.
⁸ Houston Methodist Hospital, Houston, TX, USA.
⁹ Celgene Corporation, Summit, NJ, USA.
¹⁰ University of Kansas Medical Center, Kansas City, KS, USA.
¹¹ Mayo Clinic, Phoenix, AZ, USA.

Abstract

In the original publication of the article the author has found few incorrect values in the Table 1.